ArticleMolecular biomedicine2026
Superparamagnetic iron oxide nanoparticle-driven 3-aroyl-1,4-diarylpyrrole nanocomposites (ARDAP@SPION-PEI) mediate renal cancer cell PANoptosis by regulating chromatin accessibility.
Article in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The renal cancer stem cells (RCSCs) have highly proliferation, resistance to radiotherapy and chemotherapy, and enhanced invasive and tumorigenic capacities characteristics. 3-Aroyl-1,4-diarylpyrrole (ARDAP) is a potent microtubule inhibitor developed by our team; however, its specific killing effects on RCSCs remain unknown. Furthermore, clinical application of ARDAP is restricted by shortcomings such as poor water solubility and low utilization rates. Here, we developed polyethylenimine-coated superparamagnetic iron oxide nanoparticles loaded with ARDAP (ARDAP@SPION-PEI) to overcome these barriers and evaluated their efficacy in mouse RCSCs (mRCSCs) and zebrafish. In vitro and in vivo experiments demonstrated that ARDAP@SPION-PEI significantly inhibited mRCSCs proliferation, migration, and tumorigenicity while suppressing angiogenesis in zebrafish. ARDAP@SPION-PEI treatment significantly upregulated the expression of key PANoptosis pathway genes. Assay for transposase-accessible chromatin using sequencing revealed widespread chromatin accessibility alterations, with prominent enrichment of the transcription factor zinc finger protein 148 (ZFP148). Luciferase reporter assays demonstrated that ZFP148 directly bound to and activated promoters of key PANoptosis-related genes, including receptor-interacting serine/threonine kinase 3 (Ripk3), gasdermin D (Gsdmd), IL-1β (Il1b), and caspase-1 (Casp1). Chromatin immunoprecipitation-polymerase chain reaction further showed significantly enhanced promoter occupancy at the histone H3 lysine 4 trimethylation site following treatment, indicating transcriptionally active chromatin states. Silencing ZFP148 attenuated gene activation and reduced cell death induction. In conclusion, ARDAP@SPION-PEI induces mRCSC PANoptosis by remodeling chromatin structure to promote ZNF148-mediated transcription, offering a promising epigenetic-based nanotherapeutic strategy for renal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.